Early initiation of SGLT2 inhibitors benefit Heart failure p
In a systemic review and meta-analysis, the researchers searched PubMed, Web of Science, Cochrane Library, and Embase (OVID interface) for eligible trials that randomly assigned adults with heart failure to SGLT2 inhibitors or controls.

They included overall, 8 trials with more than 15000 participants. They reconstructed time-to-event individual patient data from published Kaplan–Meier plots and calculated time-varying risk ratios (RRs) were calculated in half-, 1-, and 2-year time frames; and anticipated absolute benefits were calculated using simple models applying relative effects to baseline risks.

SGLT-2 inhibitors reduce hospitalization for heart failure by 37% (95% CI, 25% to 47%) at 6 months, 32% (CI, 20% to 42%) at 1 year, and 26% (CI, 10% to 40%) at 2 years (all high certainty) and reduce cardiovascular death by 14% (CI, 1% to 25%) at 1 year (high certainty); retarded progress of kidney disease.

Among people with heart failure, SGLT2 inhibitors reduce hospitalizations for heart failure regardless of the presence of diabetes. Clinicians should note the increased risk for genital infection in patients receiving SGLT2 inhibitors.

Source: https://doi.org/10.7326/M21-4284